核心医疗完成超1亿美元D轮融资，700+台植入量铸就人工心脏行业龙头企业

Core Insights - Core Medical has successfully secured over $100 million in Series D financing, marking the largest market-oriented financing in China's innovative medical device sector from 2025 to date, and the highest amount in the artificial heart industry in China to date [1][2] - The funding will be utilized for the incubation of original and disruptive frontier technologies, accelerating product development, and enhancing international competitiveness [1][4] - Core Medical aims to lead the global artificial heart industry with its innovative capabilities and strategic international expansion [1][4] Product Development and Market Position - Core Medical has developed a comprehensive product matrix for heart failure treatment, transitioning from "Best-in-Class" to "First-in-Class" with multiple globally pioneering products [2][4] - The company has introduced the DuoCor® integrated full magnetic suspension dual ventricular assist system, addressing the long-term treatment challenges for right heart and biventricular failure patients [2][3] - The Corheart® 6, the world's smallest and lightest left ventricular assist device (LVAD), has achieved a market share of 46% in China by 2024, with over 700 clinical applications to date [3][4] Clinical Trials and International Strategy - Core Medical is the first Chinese company to conduct overseas clinical trials in the artificial heart sector, having successfully completed its first trial in Europe in May 2024 [4][5] - The company’s CorVad® series products are designed to complement implanted devices, providing comprehensive support for various clinical scenarios [5] - Recent policy changes have included artificial hearts in the medical insurance directory in multiple regions, significantly reducing the economic burden on end-stage heart failure patients and promoting the technology's accessibility [5]